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Jean Sibilia,1 Martin Soubrier,10 Olivier Vittecoq,11 Gabriel Baron,4 Arnaud Constantin,12  
Philippe Ravaud,13 Xavier Mariette,14 on behalf of the French Society of Rheumatology and the 
investigators participating in AIR, ORA, and REGATE registries
ABSTRACT
OBJECTIVE
To compare the effectiveness and safety of three non-
tumour necrosis factor (TNF) α inhibitors (rituximab, 
abatacept, and tocilizumab) in the treatment of 
rheumatoid arthritis.
DESIGN
Population based prospective study.
SETTING
53 university and 54 non-university clinical centres in 
France.
PARTICIPANTS
3162 adults (>18 years) with rheumatoid arthritis 
according to 1987 American College of Rheumatology 
criteria, enrolled in one of the three French Society 
of Rheumatology registries; who had no severe 
cardiovascular disease, active or severe infections, or 
severe immunodeficiency, with follow-up of at least 24 
months.
INTERVENTION
Initiation of intravenous rituximab, abatacept, or 
tocilizumab for rheumatoid arthritis.
MAIN OUTCOME MEASURE
The primary outcome was drug retention without 
failure at 24 months. Failure was defined as all cause 
death; discontinuation of rituximab, abatacept, 
or tocilizumab; initiation of a new biologic or a 
combination of conventional disease modifying 
antirheumatic drugs; or increase in corticosteroid 
dose >10 mg/d compared with baseline at two 
successive visits. Because of non-proportional 
hazards, treatment effects are presented as life 
expectancy difference without failure (LEDwf), which 
measures the difference between average duration of 
survival without failure.
RESULTS
Average durations of survival without failure were 19.8 
months for rituximab, 15.6 months for abatacept, and 
19.1 months for tocilizumab. Average durations were 
greater with rituximab (LEDwf 4.1, 95% confidence 
interval 3.1 to 5.2) and tocilizumab (3.5, 2.1 to 
5.0) than with abatacept, and uncertainty about 
tocilizumab compared with rituximab was substantial 
(−0.7, −1.9 to 0.5). No evidence was found of 
difference between treatments for mean duration of 
survival without death, presence of cancer or serious 
infections, or major adverse cardiovascular events.
CONCLUSION
Among adults with refractory rheumatoid arthritis 
followed-up in routine practice, rituximab 
and tocilizumab were associated with greater 
improvements in outcomes at two years compared 
with abatacept.
Introduction
Although tumour necrosis factor (TNF) α inhibitors 
have greatly improved the daily quality of life of people 
with rheumatoid arthritis,1 as much as one third of 
patients fail to respond to anti-TNF agents.2 Alternative 
and more recently approved non-TNF targeted biologic 
agents include rituximab (a B lymphocyte depleting 
agent), abatacept (targets T cell co-stimulation), and 
tocilizumab (an interleukin 6 receptor inhibitor). These 
three drugs have demonstrated efficacy compared with 
placebo but have not been compared with each other 
in randomised controlled trials.3-5 Network meta-
analyses of randomised, placebo controlled trials have 
been conducted, but by definition they concerned 
highly selected patients.6-8
Disease activity is usually higher and comorbidities 
less common in randomised controlled trials than in 
real life. Co-treatment with methotrexate, known to 
improve the effectiveness of biologics, is less common 
in real life than in randomised controlled trials. 
In addition, the primary outcomes of randomised 
controlled trials are evaluated in the short term 
(usually 6-12 months) and therefore the long term 
drug retention rate and corticosteroid sparing effect—
WHAT IS ALREADY KNOWN ON THIS TOPIC
In patients with rheumatoid arthritis, non-TNF targeted biologic agents, including 
rituximab (a B cell depleting agent), abatacept (targeting T cell costimulation), 
and tocilizumab (an interleukin 6 receptor inhibitor) have shown efficacy 
compared with placebo
These three biologic agents have not been compared against each other in 
randomised controlled trials
Randomised controlled head-to-head comparisons of these three drugs will 
probably never be performed
WHAT THIS STUDY ADDS
Among adults with refractory rheumatoid arthritis followed-up in routine practice, 
treatment with rituximab or tocilizumab was associated with larger improvements 
in outcomes at two years compared with abatacept
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two relevant markers of effectiveness—cannot be 
analysed. Finally, short term follow-up in randomised 
controlled trials limits the analysis of serious adverse 
events—notably, serious infections and cancers.
For these reasons registry data are useful to 
complement data from randomised controlled trials 
to investigate the external validity of drugs in routine 
practice. Furthermore, only a few studies have 
compared the effectiveness and safety of biologics, and 
these mainly focused on different anti-TNF agents.9 It 
is highly probable that randomised controlled head-
to-head comparisons of rituximab, abatacept, and 
tocilizumab will never be performed. As prospective 
academic registries and comparative effectiveness 
research now allow for the so far poorly addressed 
comparisons of non-TNF targeted biologics, we 
investigated the effectiveness of rituximab, abatacept, 
and tocilizumab in the treatment of longstanding and 
refractory rheumatoid arthritis.
Methods
Study data
The French Society of Rheumatology sponsors three 
registries: Autoimmunity and Rituximab (AIR), Orencia 
and Rheumatoid Arthritis (ORA), and REGistry–
RoAcTEmra (REGATE). These registries contain only 
observational and non-interventional studies. The 
objectives of these registries are to determine and 
compare the effectiveness and safety of intravenous 
rituximab, abatacept, and tocilizumab in routine 
practice, and they aim to enrol most patients in 
France who initiated these drugs as soon as they were 
marketed.
The methodology of these registries has been 
reported.10 Their methodology was similar on 
purpose because we wanted to compare the three 
drugs. Briefly, the French Society of Rheumatology 
sent regular mail and “push” emails to all French 
rheumatology departments and physicians prescribing 
biologics for rheumatoid arthritis on approval of these 
three biologics; the emails asked for the physician’s 
agreement to participate in each registry. Such consent 
involved agreement to regular visits to the hospital 
pharmacy by a trained clinical nurse to obtain the 
list of patients receiving an intravenous infusion of 
rituximab, abatacept, or tocilizumab in the physician’s 
department; subsequent frequent access by clinical 
nurses to patient charts; limiting missing data in patient 
charts on key prespecified items (eg, treatment, disease 
activity score) and the risk of lost to follow-up; and 
allowing the French Society of Rheumatology to contact 
the patients’ general practitioners and rheumatologists, 
or the patients themselves, to obtain missing follow-up 
data. Twenty six trained clinical study nurses in each 
registry visited each centre to collect effectiveness and 
safety data from patient charts at the same prespecified 
intervals, independently of disease severity or drug 
mode of administration: at drug initiation and at three 
months and every six months thereafter or at drug 
discontinuation and after drug discontinuation for seven 
years. Even after drug discontinuation, a systematic 
follow-up for safety was performed. All information was 
drawn from the clinical charts. Data were collected in an 
electronic case report form (https://194.206.215.54/
PR/index.ecrf, https://194.206.215.102/index.ecrf, 
and https://194.206.215.149/index.ecrf, for AIR, ORA, 
and REGATE, respectively).
Two clinical research assistants performed random 
on-site monitoring to control for the quality of collected 
data and to obtain data considered missing by study 
nurses. In addition, a summary of collected data for 
key items for each enrolled patient was sent once a year 
to each centre after the initiation of the registries. In 
case of serious adverse events (death; cancers; serious 
infections, defined as those requiring intravenous 
antibiotics, hospital admission, or resulting in 
death; and major cardiovascular events (ie, death of 
cardiovascular origin, stroke, myocardial infarction)), 
study nurses were asked to send a copy of the chart to 
each registry coordinator. All serious adverse events 
were adjudicated by the registry coordinators (JEG, JM, 
and XM).
Treatment groups and follow-up
Using observational data, we compared three groups 
of people with rheumatoid arthritis (those initiating 
intravenous rituximab, abatacept, or tocilizumab) at 
24 month follow-up.11
Eligibility criteria
From September 2005 to August 2013, we recruited 
patients aged more than 18 years from 107 clinical 
centres in France. The inclusion criteria were diagnosis 
of rheumatoid arthritis according to the 1987 American 
College of Rheumatology criteria, age more than 18 
years, and initiation of intravenous treatment with 
rituximab, abatacept, or tocilizumab before March 
2013 (inclusion at least two years before database was 
locked in March 2015 to ensure a minimal theoretical 
follow-up of two years for all patients). The exclusion 
criteria were contraindications to any of the three 
biologics (rituximab, abatacept, or tocilizumab): severe 
cardiovascular disease, active or severe infections, 
severe immunodeficiency, or previous use of any of these 
three biologics. We obtained the list of patients receiving 
intravenous rituximab, abatacept, or tocilizumab 
in each centre from the pharmacist of the hospitals. 
Therefore all consecutive patients receiving one of the 
three drugs at the time of the study were included in 
each centre, which limited inclusion bias.
Endpoints
The primary endpoint was drug treatment retention 
without failure at month 24. Lack of failure was 
included in this context because rituximab is 
administered intermittently, and therefore it would 
be difficult to determine retention without such 
information. Failure was defined as all cause death, 
discontinuation of the drug studied in the registry, 
initiation of a combination of conventional disease 
modifying antirheumatic drugs (DMARDs), a new 
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biologic, or increase in oral corticosteroids dose more 
than 10 mg/d at two consecutive visits compared with 
the baseline dose.
Secondary endpoints included European League 
Against Rheumatism (EULAR) response at months 
6, 12, and 24. A good EULAR response was defined 
as a decrease in disease activity score in 28 joints—
erythrocyte sedimentation rate (DAS28-ESR) more 
than 1.2 points and resulting score 3.2 or less. A 
moderate EULAR response was defined as a decrease 
in DAS28-ESR more than 0.6 points and resulting score 
5.1 or less. Because the data were not systematically 
recorded at exact fixed times, we used a two month 
window (the closest information to the time within two 
months before or after this time).
Safety endpoints included time to first serious 
adverse events (among serious infection, major 
adverse cardiovascular events (MACEs), cancer, and 
death). Each component of this composite endpoint 
was considered separately. We defined a serious 
infection as an infection requiring hospital admission, 
requiring intravenous antibiotics, or resulting in death. 
MACEs were defined as death of cardiovascular origin, 
stroke, or myocardial infarction. Serious infections, 
MACEs, cancer, and death were considered in the 
analysis regardless of their time of occurrence, even 
after discontinuation of the study drug.
Statistical analysis
We used a propensity score approach to account 
for differences in observed factors that might affect 
both treatment assignment and outcome. The 
propensity score was defined as the probability of a 
patient receiving the drug effectively initiated among 
rituximab, abatacept, and tocilizumab, based on 
patient covariates. Covariate selection was prespecified 
and based on a non-parsimonious approach to account 
for both potential confounding factors and variables 
that can serve as proxies for unknown or unmeasured 
confounding variables.
Not meeting inclusion criteria*
Age <18 or missing value (n=1)
Less than 4 ACR 1987 criteria or missing value (n=8)
Contraindicator for any of the three treatments or missing value (n=122)†
History of one of the three treatments or missing value (n=38)
Outside inclusion period or missing value (n=1)‡
6
40
10
666
59
Rituximab registry1947 Abatacept registry823 Tociluzimab registry1364
Analysed
With failure
Censored patients before
  end of follow-up
Drug retention without failure
263
286
389
Patients with <2 years of
follow-up (including 5
patients with no follow-up)
Eligible patients
Patients in rituximab registry
938
Patients with complete follow-up§
With failure (including 4
  deaths)
Drug retention without failure
  (including 2 deaths)
263
389
652
Patients with complete follow-up§
With failure (including 28
  deaths)
Drug retention without failure
  (including 30 deaths)
347
252
599
Patients with complete follow-up§
With failure (including 40
  deaths)
Drug retention without failure
  (including 123 deaths)
515
1053
Excluded
No follow-up3
3
Analysed
With failure
Censored patients before
  end of follow-up
Drug retention without failure
347
11
252
610
Excluded
No follow-up13
Analysed
With failure
Censored patients before
  end of follow-up
Drug retention without failure
515
46
1053
Excluded
No follow-up5
5
3183
Patients enrolled in the three registries
4134
1614
1568
1619
Patients in abatacept registry Patients in tociluzimab registry
13
51
Patients with <2 years of
follow-up (including 13
patients with no follow-up)
24
Patients with <2 years of
follow-up (including 3
patients with no follow-up)
623
951
941
289
Fig 1 | Flow of participants through study. *Not meeting one of the inclusion criteria (n=781) or missing value for at 
least one inclusion criterion (n=170). †Severe cardiovascular disease, active or severe infections, severe immune 
deficiency. ‡Inclusion period: patients who initiated treatment before March 2013 (ie, two years before database was 
locked, in March 2015, to have at least two years of theoretical follow-up). §Patients with treatment failure before two 
years of follow-up or with at least two years of follow-up. ACR=American College of Rheumatology
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We used a multinomial logistic model to calculate 
the probability of a patient receiving the treatment 
effectively initiated among rituximab, abatacept, 
and tocilizumab to address the initial confounding 
between the three drugs. Propensity was estimated 
by using a multinomial logistic model with the drug 
received as the dependent variable and the following 
baseline factors as independent variables: age; disease 
duration; sex; history of serious or recurrent infection, 
cancer, MACE, cardiac insufficiency, renal insufficiency, 
hepatic disease, respiratory disease, extra-articular 
involvement, smoking, diabetes, arterial hypertension, 
dyslipidemia, γ globulin level, IgG and IgM levels, 
neutropenia, positive rheumatoid factor or antibodies 
against cyclic citrullinated peptides; number of previous 
conventional synthetic DMARDs; number of previous 
anti-TNF drugs; disease activity at initiation of study 
drug (number of tender joints, number of swollen joints, 
erythrocyte sedimentation rate, C reactive protein level, 
patient global assessment of disease activity, DAS28-
ESR), co-treatment at initiation of study drug, including 
concomitant conventional synthetic DMARDs received 
and daily dose of corticosteroids; and number of 
patients receiving each treatment in the patient’s centre.
Table 1 | Baseline characteristics of participants. Values are numbers (percentages) of participants unless stated otherwise
Characteristics
Unweighted cohort Weighted cohort
Rituximab (n=1614) Abatacept (n=610) Tocilizumab (n=938) Rituximab (n=1548) Abatacept (n=620) Tocilizumab (n=964)
Mean (SD) age (years) 58.0 (12.7) 59.7 (13.8) 56.5 (13.9) 58.1 (12.9) 57.3 (14.1) 57.9 (14.1)
Median (interquartile range) 
disease duration (years) 11.0 (6.0-18.0) 11.0 (5.0-19.0) 8.0 (3.0-16.0) 10.0 (5.0-18.0) 11.0 (5.0-18.0) 12.0 (5.0-21.0)
Women 1287 (79.7) 478 (78.4) 741 (79.0) 1243 (80.3) 491 (79.2) 765 (79.4)
Past serious or recurrent infection 565 (35.0) 206 (33.8) 112 (11.9) 446 (28.8) 171 (27.6) 305 (31.6)
History of cancer 232 (14.4) 32 (5.3) 39 (4.2) 158 (10.2) 55 (8.9) 69 (7.1)
Rheumatoid factor positive 1237 (80.5) 412 (75.0) 627 (79.8) 1154 (79.0) 448 (80.0) 665 (77.5)
Anti-CCP antibody positive 1074 (77.0) 382 (74.3) 631 (82.8) 1023 (76.4) 1023 (76.4) 1023 (76.4)
Median No (interquartile range) 
of previous anti-TNF agents 2.0 (1.0-2.0) 2.0 (1.0-2.0) 1.0 (0.0-2.0) 2.0 (1.0-2.0) 2.0 (1.0-2.0) 2.0 (1.0-2.0)
Median No (interquartile range) 
of conventional DMARDs 3.0 (2.0-4.0) 2.0 (1.0-4.0) 2.0 (1.0-3.0) 3.0 (2.0-4.0) 3.0 (2.0-4.0) 2.0 (1.0-4.0)
Median No (interquartile range) 
of tender joints 9.0 (5.0-15.0) 8.0 (3.0-15.0) 7.0 (3.0-13.0) 8.0 (4.0-15.0) 8.0 (3.0-14.0) 8.0 (4.0-12.0)
Median No (interquartile range) 
of swollen joints 6.0 (3.0-10.0) 5.0 (2.0-9.0) 5.0 (2.0-8.0) 6.0 (3.0-10.0) 6.0 (2.0-10.0) 5.0 (2.0-10.0)
Median (interquartile range) ESR 32.0 (17.0-51.0) 28.0 (15.0-50.0) 27.0 (13.0-48.0) 31.0 (16.0-50.0) 29.0 (16.0-45.0) 28.0 (15.0-47.0)
Median (interquartile range) CRP 
level 16.0 (5.6-38.0) 13.0 (4.8-28.5) 12.5 (4.0-32.0) 13.0 (5.0-36.0) 13.9 (5.0-28.0) 15.0 (5.0-37.0)
Mean (SD) patient global assess-
ment of disease activity  
(range 0-100)
61.5 (22.0) 59.7 (22.8) 57.8 (24.7) 60.4 (22.3) 62.9 (21.9) 57.0 (26.4)
Mean (SD) DAS28-ESR 5.5 (1.2) 5.2 (1.3) 5.0 (1.4) 5.4 (1.3) 5.3 (1.3) 5.3 (1.3)
Concomitant treatment with 
conventional DMARD 1043 (64.9) 401 (66.5) 556 (59.5) 984 (63.8) 387 (62.9) 585 (60.9)
Corticosteroids 1242 (77.7) 456 (74.4) 623 (66.5) 1133 (74.3) 460 (74.9) 684 (71.2)
Mean (SD) corticosteroids dose* 
(mg/d) 11.8 (8.8) 11.2 (8.3) 10.3 (7.2) 11.3 (8.3) 11.6 (8.5) 11.2 (7.2)
CCP=cyclic citrullinated peptide; TNF=tumour necrosis factor; DMARD=disease modifying antirheumatic drug; ESR=erythrocyte sedimentation rate; CRP=C reactive protein; DAS28-ESR=Disease 
Activity Score in 28 joints-erythrocyte sedimentation rate.
Unweighted cohort, raw data; weighted cohort, pseudo-population obtained after inverse probability weighting.
*Only concerns participants receiving corticosteroids.
Table 2 | Causes of drug failure at 24 month follow-up. Values are numbers (percentages) of participants
Causes of drug failure
Unweighted cohort Weighted cohort
Rituximab 
(n=515)
Abatacept 
(n=347)
Tocilizumab 
(n=263)
Rituximab 
(n=480)
Abatacept 
(n=373)
Tocilizumab 
(n=315)
Death 26 (5.0) 19 (5.5) 4 (1.5) 25 (5.3) 20 (5.3) 14 (4.3)
Introduction of a new biologic DMARD or combination of 
DMARDs
206 (40.0) 128 (36.9) 171 (65.0) 185 (38.6) 164 (44.1) 215 (68.3)
Discontinuation of biologic 454 (88.2) 322 (92.8) 241 (91.6) 424 (88.5) 347 (93.1) 288 (91.3)
Cause of discontinuation:
 Death 4 (0.9) 0 (0.0) 2 (0.9) 3 (0.7) 0 (0.0) 4 (1.4)
 Adverse event 64 (14.1) 58 (18.0) 97 (41.6) 66 (15.7) 58 (16.6) 115 (42.5)
 Inefficacy 332 (73.1) 205 (63.7) 107 (45.9) 306 (72.1) 224 (64.7) 121 (44.5)
 Other reason 54 (11.9) 59 (18.3) 27 (11.6) 49 (11.5) 65 (18.7) 31 (11.6)
 Increase of corticosteroids dose (>10 mg/d of baseline) 2 (0.4) 6 (1.7) 4 (1.5) 2 (0.5) 5 (1.5) 3 (1.0)
DMARD=disease-modifying antirheumatic drug.
Unweighted cohort, raw data; weighted cohort, pseudo-population obtained after inverse probability weighting.
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The analysis was based on inverse probability 
weighting12; patients were each weighted by the inverse 
probability that they would receive the treatment 
effectively initiated among rituximab, abatacept, or 
tocilizumab, allowing average treatment effects to be 
estimated. Stabilised weights were used to reduce the 
variability of weights and standard errors of estimated 
treatment effects.13 We used multiple imputation by 
chained equation, using all baseline variables of the 
propensity score model as well as the drug received 
to impute missing values for variables included in 
the propensity score approach. Ten independent 
imputed datasets were generated. For each dataset, 
we estimated a propensity score and pooled the 
resulting scores according to Rubin’s rules. Covariate 
balance was checked after weighting by computing 
standardised differences. A standardised difference of 
10% or more is generally considered meaningful.14
We estimated survival without failure using weighted 
Kaplan-Meier product limit estimator. According to the 
Grambsch and Therneau test15 (P<0.001), proportional 
hazards assumption of the planned marginal Cox 
model was violated (see supplementary eTable 1). 
Restricted mean survival times (ie, area under the 
curve between the time of inclusion and end of 
follow-up) were computed by numerical integration 
of the Kaplan-Meier curve for each drug (rituximab, 
abatacept, or tocilizumab) in the weighted cohort.16 
Restricted mean survival time measures the average 
duration of survival without failure for each drug 
over the follow-up period. To quantify the between 
group differences, we calculated the life expectancy 
difference without failure (LEDwf, difference between 
restricted mean survival times) and the life expectancy 
ratio without failure (LERwf, ratio of restricted mean 
survival times) and their 95% confidence intervals 
with normal approximation (estimated by bootstrap 
with 1000 replications).17 Statistical significance for 
these analyses was indicated by a 95% confidence 
interval for the LERwf that excludes 1 or for the LEDwf 
that excludes 0. Patients were analysed in the groups 
to which they were initially treated. Three sensitivity 
analyses were performed for the primary outcome 
(results were expressed as LEDwf, 95% confidence 
interval). In the first analysis, we computed estimates 
in the unweighted cohort. Secondly, we used truncated 
weights (with truncation at the fifth and 95th centiles) 
to analyse the influence of extreme weights in the 
weighted cohort. Thirdly, to evaluate the consistency 
of our analyses regarding the definition of failure, we 
duplicated our main analysis (in the weighted cohort) 
with three alternative definitions of failure: death or 
discontinuation of the study drug, death or initiation of 
a combination of conventional DMARDs or a biologic 
DMARD, and death or discontinuation of the study 
drug or initiation of a combination of conventional 
DMARDs or a biologic DMARD.
To compare EULAR response, we used logistic 
regression with weighted generalised estimating 
equations, with drug as the only covariate. We considered 
participants to be EULAR non-responders if they 
discontinued the study drug or initiated a combination 
of conventional DMARDs, or a new biologic, or increased 
dosage of oral corticosteroids greater than 10 mg/d at two 
consecutive visits. Results for this outcome are expressed 
as odds ratio and 95% confidence intervals.
Survival without serious adverse events was 
estimated globally and for each type of event (serious 
infection, MACE, cancer, death) by weighted Kaplan-
Meier product limit estimator. We estimated the 
average durations of survival without serious adverse 
events in each drug group over the follow-up period by 
restricted mean survival times and compared these by 
using LEDwf and LERwf (and 95% confidence intervals) 
in the weighted cohort.
Statistical analyses were carried out in SAS 9.4 (SAS 
Institute, Cary, NC) and R 3.2.2 (R Core Team, 2015, R 
Foundation for Statistical Computing, Vienna, Austria, 
www.R-project.org/).
Patient and public involvement
Patients were not involved in the design of the study. 
Since data were being retrospectively analysed, patients 
Table 3 | Survival without failure at 24 months
Weighting
Rituximab Abatacept Tocilizumab
No of failures
% surviving without 
failure (95% CI) No of failures
% surviving without 
failure (95% CI) No of failures
% surviving without 
failure (95% CI)
Unweighted 515 67.6 (65.2 to 69.8) 347 42.5 (38.5 to 46.4) 263 68.0 (64.6 to 71.1)
Weighted 480 68.6 (65.3 to 71.5) 373 39.3 (34.1 to 44.5) 315 63.4 (56.1 to 69.8)
Unweighted cohort, raw data; weighted cohort, pseudo-population obtained after inverse probability weighting.
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Fig 2 | Kaplan-Meier curves of drug retention without 
failure at 24 months (after inverse probability weighting). 
Vertical bars represent censored patients
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could not effectively contribute to improvements on 
the study design.
Results
Baseline characteristics of patients and follow-up
From September 2005 to June 2013, the AIR, ORA, and 
REGATE registries included 4134 patients (rituximab, 
1947 patients from September 2005 to January 2010; 
abatacept, 823 from January 2007 to October 2010; 
and tocilizumab, 1364 from April 2010 to June 2013) 
from 107 centres: 53 university and 54 non-university 
centres (86 centres participated in AIR, 82 in ORA, 
77 in REGATE, and 53 in all three registries) (fig 1). 
Among the 4134 enrolled patients, 3183 fulfilled 
the eligibility criteria for analysis, and data for 3162 
could be analysed at 24 months. The database was 
frozen in March 2015 for the present analysis. Baseline 
characteristics for the three drug groups differed in the 
unweighted cohort (table 1 and supplementary eTable 
2), notably in median duration of disease (rituximab: 
11 years (interquartile range 6-18); abatacept: 11years 
(5-19); tocilizumab: 8 years (3-16)); history of cancer 
(14.4%, 5.3%, and 4.2% of patients, respectively); 
rheumatoid factor positivity (80.5%, 75.0%, and 
79.8% of patients, respectively); disease activity (mean 
DAS28-ESR 5.5 (SD 1.2), 5.2 (1.3), and 5.0 (1.4), 
respectively); and co-treatment with a conventional 
DMARD (64.9%, 66.5%, and 59.5% of patients, 
respectively) or corticosteroids (prednisone: 77.7%, 
74.4%, and 66.5% of patients, respectively).
Propensity weighted analysis
Propensity scores were calculated for 3162 patients. 
Weights ranged from 0.2 to 31.2. The weighted groups 
were well balanced for recorded baseline variables, 
with standardised differences ranging from 0% to 25% 
and exceeding 10% for only 16 of the 99 comparisons 
(table 1, and supplementary eTable 2, eTable 3, and 
eFigure 1).
Effectiveness results
Table 2 describes the causes of drug failure (all cause 
death; discontinuation of the study drug; initiation 
of a combination of conventional DMARDs, or a 
new biologic; increase of oral corticosteroids dose 
>10 mg/d at two consecutive visits compared with 
baseline). At month 24 (weighted cohort), 68.6% of 
patients (95% confidence interval 65.3% to 71.5%) 
  Primary analysis (weighted)
  Unweighted
  Truncation*
Definition of failure†
  Definition 1
  Definition 2
  Definition 3
4.1 (3.1 to 5.2)
3.3 (2.6 to 4.0)
3.5 (2.6 to 4.3)
4.2 (3.2 to 5.3)
2.4 (1.3 to 3.5)
4.0 (3.0 to 5.1)
-3 -2 -1 1 20 3 4 5 6
LED RTX v ABA
(95% CI)
LED RTX v ABA
(95% CI)
1548
1614
1448
1548
1548
1548
Rituximab
620
610
544
620
620
620
Abatacept
No of patients included
in each analysis
19.8
19.5
19.6
20.0
21.5
19.8
Rituximab
15.6
16.2
16.1
15.8
19.1
15.8
Abatacept
RMST (months)
Fig 3 | Sensitivity analyses of drug retention without failure at month 24 for abatacept and rituximab. RMST=restricted 
mean survival time; LED=life expectancy difference (difference between RMST); RTX=rituximab; ABA=abatacept. 
*Truncated weights used in weighted cohort. †1=death or discontinuation of study drug; 2=death or initiation of 
a combination of conventional disease modifying antirheumatic drugs (DMARDs) or a biologic DMARD; 3=death or 
discontinuation of study drug or initiation of a combination of conventional DMARDs or biologic DMARD
  Primary analysis (weighted)
  Unweighted
  Truncation*
Definition of failure†
  Definition 1
  Definition 2
  Definition 3
3.5 (2.1 to 5.0)
3.5 (2.7 to 4.4)
3.2 (2.3 to 4.2)
3.6 (2.1 to 5.1)
1.2 (-0.3 to 2.7)
3.4 (1.9 to 4.9)
-3 -2 -1 1 20 3 4 5 6
LED TOC v ABA
(95% CI)
LED TOC v ABA
(95% CI)
964
938
742
964
964
964
Tocilizumab
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610
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Abatacept
19.1
19.8
19.3
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20.2
19.1
Tocilizumab
15.6
16.2
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15.8
19.1
15.8
Abatacept
RMST (months)
No of patients included
in each analysis
Fig 4 | Sensitivity analyses of drug retention without failure at month 24 for abatacept and tocilizumab. 
RMST=restricted mean survival time; LED=life expectancy difference (difference between RMST); TOC=tocilizumab; 
ABA=abatacept. *Truncated weights used in weighted cohort. †1=death or discontinuation of study drug; 2=death or 
initiation of a combination of conventional disease modifying antirheumatic drugs (DMARDs) or a biologic DMARD; 
3=death or discontinuation of study drug or initiation of a combination of conventional DMARDs or biologic DMARD
 o
n
 9 August 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l67 on 24 January 2019. Downloaded from 
RESEARCH
the bmj | BMJ 2019;364:l67 | doi: 10.1136/bmj.l67 7
were still using rituximab without failure, 39.3% 
(34.1% to 44.5%) were using abatacept, and 63.4% 
(56.1% to 69.8%) were using tocilizumab (table 3, 
fig 2). Average durations of survival without drug 
failure estimated by restricted mean survival times 
were 19.8 months for rituximab, 15.6 months 
for abatacept, and 19.1 months for tocilizumab. 
Restricted mean survival times for LEDwf were greater 
with rituximab (4.1, 95% confidence interval 3.1 
to 5.2) and tocilizumab (3.5, 2.1 to 5.0) than with 
abatacept, as well as LERwf (1.26, 1.18 to 1.35, 
and 1.22, 1.12 to 1.33, respectively). Uncertainty 
about tocilizumab compared with rituximab was 
substantial (LEDwf −0.7, −1.9 to 0.5; LERwf 0.97, 0.91 
to 1.03; figs 3-5). At month 24, more participants 
treated with rituximab or tocilizumab than with 
abatacept showed a good or moderate EULAR 
response (table 4, eTable 4).
Safety
At month 24 (weighted cohort), 436 patients had 
experienced at least one adverse event of serious 
infection, MACE, cancer, or death: 224 (14.5%) in 
the rituximab group, 101 (16.2%) in the abatacept 
group, and 111 (11.6%) in the tocilizumab group 
(table 5). Table 6 and figure 6 describe survival without 
serious adverse events among the three drug groups. 
Average durations of survival without serious adverse 
events were 22.1 months for rituximab, 21.8 months 
for abatacept, and 22.3 months for tocilizumab. 
No evidence of a difference in average duration of 
survival without serious adverse events was found 
with rituximab or tocilizumab versus abatacept in 
terms of LED without serious adverse events (0.3, 95% 
confidence interval −0.4 to 1.0 and 0.5, −0.4 to 1.4, 
respectively) nor with tocilizumab versus rituximab 
(0.2, −0.4 to 0.9). Results in terms of LERs without 
serious adverse events were similar, with no evidence 
of a difference with rituximab or tocilizumab versus 
abatacept (1.01, 0.98 to 1.05 and 1.02, 0.98 to 1.06, 
respectively) nor with tocilizumab versus rituximab 
(1.01, 0.98 to 1.04).
Additional analyses
Figures 3-5 present the findings of sensitivity analysis 
(unweighted cohort, truncated weights, three 
definitions of failure).
Discussion
The present study found that drug retention without 
failure at month 24 was better in patients treated with 
rituximab or tocilizumab than in those treated with 
abatacept. Drug retention seems a good surrogate 
marker of the balance between effectiveness and 
adverse events and appears particularly adequate in 
registry studies and relevant in routine practice. We 
chose month 24 for the primary endpoint so that we 
could study drug retention in the long term and because 
that duration corresponded to the median follow-
up time in the most recent registry (the tocilizumab 
registry, which therefore had a higher rate of losses to 
follow-up given its more recent onset).
  Primary analysis (weighted)
  Unweighted
  Truncation*
Definition of failure†
  Definition 1
  Definition 2
  Definition 3
-0.7 (-1.9 to 0.5)
0.3 (-0.3 to 0.9)
-0.3 (-1.0 to 0.5)
-0.7 (-1.8 to 0.5)
-1.3 (-2.4 to -0.1)
-0.7 (-1.9 to 0.5)
-3 -2 -1 1 20 3 4 5 6
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(95% CI)
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Fig 5 | Sensitivity analyses of drug retention without failure at month 24 for rituximab and tocilizumab. 
RMST=restricted mean survival time; LED=life expectancy difference (difference between RMST); TOC=tocilizumab; 
RTX=rituximab. *Truncated weights used in weighted cohort. †1=death or discontinuation of study drug; 2=death or 
initiation of a combination of conventional disease modifying antirheumatic drugs (DMARDs) or a biologic DMARD; 
3=death or discontinuation of study drug or initiation of a combination of conventional DMARDs or biologic DMARD
Table 4 | Comparison of moderate and good EULAR response (weighted cohort) at 6, 12, and 24 months
Follow-up time
No (%) Odds ratio (95% CI)
Rituximab Abatacept Tocilizumab ABA v RTX TOC v RTX ABA v TOC
6 months 511 (54.5) 235 (48.0) 508 (72.9) 0.77 (0.55 to 1.07) 2.26 (1.51 to 3.37) 0.34 (0.21 to 0.54)
12 months 377 (43.3) 171 (34.0) 417 (59.9) 0.66 (0.52 to 0.84) 1.98 (1.30 to 3.03) 0.33 (0.22 to 0.51)
24 months 322 (34.6) 125 (22.7) 272 (44.2) 0.55 (0.39 to 0.78) 1.51 (0.95 to 2.41) 0.37 (0.21 to 0.63)
EULAR=European League Against Rheumatism; ABA=abatacept; RTX=rituximab; TOC=tocilizumab.
Weighted cohort, pseudo-population obtained after inverse probability weighting.
EULAR non-response was considered death, discontinuation of the drug studied in the registry and/or initiation of a combination of conventional disease-
modifying antirheumatic drugs and/or a new biologic and/or increase in oral corticosteroids dose >10 mg/day at 2 consecutive visits.
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Comparison with other studies
Only a few comparative effectiveness studies have 
examined rituximab, abatacept, and tocilizumab. 
However, these studies had limited population samples, 
compared disease activity in the short term, and had 
discrepant results.18-22 Registry data on the retention 
rate of non-TNF targeted biologics, notably rituximab 
and tocilizumab, is limited. In a recent collaboration 
between nine European registries, including the 
French registry, the median crude retention rate for 
abatacept varied from 1.4 to 2.1 years depending on 
autoantibody status,23 which is similar to the median 
abatacept retention rate in the present study.
Randomised clinical trials are the standard strategy 
for drug comparisons. However, although a few trials 
compared non-TNF biologics with anti-TNF agents,24 25 
no randomised clinical trial has compared rituximab, 
abatacept, and tocilizumab with each other, and 
probably no direct head-to-head randomised clinical 
trial will compare these drugs in the future.
Strengths and limitations of this study
As with observational studies, the main limitations 
of our study are lack of randomisation and the 
channelling bias (tendency of clinicians to prescribe 
treatment based on patient’s characteristics) inherent 
in this type of study. Using observational data, we 
compared estimated drug effectiveness in three groups 
of people with rheumatoid arthritis (those initiating 
intravenous rituximab, abatacept, or tocilizumab) 
at 24 month follow-up. Drug retention is the most 
robust outcome for comparing registry based patients 
treated with different drugs. We used a propensity 
score approach to account for differences in observed 
factors that might affect both treatment assignment 
and outcome. Despite the use of such an approach, 
confounding remains a problem. Regardless of these 
limitations, observational studies are relevant to study 
effects of treatments.26
To minimise the likelihood of incorrect associations 
being observed, we included many baseline 
characteristics of participants in the propensity score, 
including comorbidities, previous treatments, disease 
activity, and co-treatments. To test the robustness of our 
results, we used truncated weights and multiple outcome 
criteria on the cohort. Results were consistent among 
these different approaches. Analysis of EULAR response 
yielded similar results to those of the primary endpoint. 
However, missing data and the differential effect of 
tocilizumab on acute phase reactants included in the 
definition of EULAR response compared with abatacept 
and rituximab should be noted (the Clinical Disease 
Activity Index, which excludes acute phase reactants, is 
not collected in AIR and ORA). Some confidence intervals 
were wide, resulting in uncertainty; particularly in the 
comparison between rituximab and tocilizumab.
Because our study included rituximab, a drug that 
is administered intermittently, we used drug retention 
Table 5 | Description of serious adverse events (SAEs) in unweighted and weighted cohorts. Values are numbers 
(percentages) of participants unless stated otherwise
Variables
Unweighted cohort Weighted cohort
Rituximab 
(n=1614)
Abatacept 
(n=610)
Tocilizumab 
(n=938)
Rituximab 
(n=1548)
Abatacept 
(n=620) Tocilizumab (n=964)
Patients with at least 
one SAE
237 (14.7) 104 (17.0) 104 (11.1) 224 (14.5) 101 (16.2) 111 (11.6)
First SAE:
 Serious infection 172 (72.6) 69 (66.3) 83 (79.8) 157 (70.2) 69 (68.5) 88 (78.9)
 Death 18 (7.6) 15 (14.4) 3 (2.9) 19 (8.4) 15 (14.3) 10 (9.1)
 Cancer 34 (14.3) 16 (15.4) 12 (11.5) 37 (16.6) 13 (13.1) 10 (8.9)
 MACE 13 (5.5) 4 (3.8) 6 (5.8) 11 (4.8) 4 (4.1) 3 (3.0)
No (rate) of events:
 Serious infections 220 (13.6) 87 (14.3) 92 (9.8) 205 (13.2) 88 (14.2) 100 (10.4)
 Death 39 (2.4) 26 (4.3) 4 (0.4) 34 (2.2) 26 (4.2) 14 (1.4)
 Cancers 42 (2.6) 19 (3.1) 17 (1.8) 43 (2.8) 14 (2.3) 17 (1.8)
 MACEs 16 (1.0) 5 (0.8) 6 (0.6) 13 (0.8) 5 (0.8) 3 (0.3)
MACE=major adverse cardiovascular event (death of cardiovascular origin, stroke, or myocardial infarction).
Unweighted cohort, raw data; weighted cohort, pseudo-population obtained after inverse probability weighting; SAE: serious adverse event (serious 
infection, major adverse cardiovascular event, cancer, or death).
Table 6 | Survival without serious adverse events (SAEs) for weighted cohort
Adverse events
Rituximab Abatacept Tocilizumab
No of 
events
% surviving without event 
(95% CI)
No of 
events
% surviving without event 
(95% CI)
No of 
events
% surviving without event 
(95% CI)
SAE 224 85.0 (82.5 to 87.2) 101 83.4 (78.5 to 87.2) 111 86.7 (80.6 to 91.1)
Serious infection 163 89.1 (86.8 to 91.0) 71 88.2 (83.8 to 91.4) 88 89.5 (83.8 to 93.3)
Death 34 97.7 (96.4 to 98.5) 26 95.7 (92.6 to 97.5) 14 98.3 (94.7 to 99.5)
Cancer 42 97.1 (95.8 to 98.1) 14 97.6 (94.9 to 98.9) 12 98.5 (94.9 to 99.6)
MACE 12 99.2 (98.3 to 99.6) 5 99.1 (96.9 to 99.7) 3 99.6 (95.8 to 99.9)
MACE=major adverse cardiovascular event (death of cardiovascular origin, stroke, or myocardial infarction).
Weighted cohort, pseudo-population obtained after inverse probability weighting; SAE: serious adverse event (serious infection, major adverse 
cardiovascular event, cancer, or death).
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without failure to avoid problems associated with 
intermittent administration. Failure was defined as 
death or initiation of a new biologic or combination of 
conventional DMARDs, or noticeable increase in oral 
corticosteroid dose (>10 mg/d from baseline). Monthly 
evaluation of drug retention before drug infusion might 
result in an earlier decision to discontinue abatacept 
or tocilizumab compared with rituximab. To limit the 
risk of rituximab being favoured over abatacept or 
tocilizumab, we chose a primary endpoint evaluation 
at month 24. The possible bias from using a different 
infusion schedule only concerns the comparison of 
abatacept with rituximab retention and not abatacept 
and tocilizumab retention (both drugs are given 
monthly).
Most of the patients enrolled in the study were 
refractory to previous treatment with anti-TNF agents. 
The results of our study therefore should not be 
extrapolated to biologic (anti-TNF) naïve patients (for 
whom abatacept and tocilizumab have marketing 
authorisations). In addition, all participants received 
intravenous abatacept and tocilizumab. Therefore, the 
characteristics and comorbidities of outpatients who 
receive subcutaneous abatacept or tocilizumab might 
differ from those of the study participants.
The strengths of our registry data include its real life 
setting (as reflected by the burden of comorbidities; in 
the ORA registry, only about 20% of patients would 
have fulfilled all the inclusion criteria for at least one 
of the pivotal controlled trials27); the large number of 
unselected patients enrolled corresponding to most 
people who initiated a non-TNF biologic (eg, >85% 
of prescriptions of rituximab in non-haematology 
and non-oncology departments between 2005 and 
200928); enrolment in university and non-university 
centres; the systematic collection at prespecified 
intervals of effectiveness and safety data from patient 
charts independent of any physician’s intervention; 
patient lists obtained from pharmacists and therefore 
the inclusion of consecutive patients in each centre 
without bias; the intravenous administration of drugs 
in hospital, which ensures adherence to treatment 
and accurate information on baseline characteristics, 
drug retention, and co-treatments; the long term 
prospective follow-up; and centralised validation of 
serious adverse events.
Conclusions and policy implications
The originality of this study is its evaluation of the 
effectiveness of non-TNF biologics in real life (most of 
the literature describes only the effect of methotrexate 
and anti-TNF agents in this setting) and in providing 
some new insights into the benefit-risk ratio of non-
TNF biologics. Serious adverse events did not differ 
between the three non-TNF biologics. Such events 
were more common in association with tocilizumab 
than with rituximab and abatacept. Therefore, the 
observed higher drug retention rate of rituximab and 
tocilizumab compared with abatacept is related to 
greater effectiveness rather than a better safety profile. 
At month 24, the study drug was discontinued in about 
30% of those using rituximab and tocilizumab and 
60% of those using abatacept, which emphasises the 
continued need for enlargement of the armamentarium 
of new biologic and targeted DMARDs in the treatment 
of rheumatoid arthritis.
In this national registry based cohort of people 
with rheumatoid arthritis, those receiving rituximab 
or tocilizumab showed a larger improvement in 
outcomes at two years than those receiving abatacept. 
These results apply to patients with longstanding and 
refractory rheumatoid arthritis who had previously 
received one or more biologics, and not biologic agent 
naïve patients with shorter disease duration.
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